Press release
OX-40 Receptor Agonist Therapeutics Analysis - Patent, Designation, Collaboration and Developments
Explore report sample at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline/report-sample
Most of the companies are focused on developing their drug candidates as monoclonal antibodies in the OX-40 receptor agonist therapeutics pipeline. Monoclonal antibodies are homogenous and consistent. Also, they can be renewably generated once a suitable hybridoma is developed and are highly sensitive to small changes in both salt concentration and ph.
Browse report at: https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline
In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into a collaboration to initiate the Phase I clinical trial designed to evaluate GSK3174998 as monotherapy in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). Some of the key players developing drugs as OX-40 receptor agonist for the treatment of various indications include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and others.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release OX-40 Receptor Agonist Therapeutics Analysis - Patent, Designation, Collaboration and Developments here
News-ID: 1181564 • Views: …
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.
CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Download report sample at: http://bit.ly/2eqiPu5
**Various collaborations for CDK inhibitors drug development
Eli Lilly…
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the…
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,…
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.…
More Releases for GlaxoSmithKline
Parp Inhibitor Market Overall Study Report 2025-2032 | AstraZeneca, GlaxoSmithKl …
PARP Inhibitor Market Size and Trends
Global PARP inhibitor market is estimated to be valued at USD 7.20 Bn in 2024 and is expected to reach USD 13.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
The latest report, titled "Parp Inhibitor Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032" by Coherent Market Insights, offers an in-depth analysis of the industry, providing…
Parp Inhibitor Market Forecasting Market Growth and Size 2024-2031| AstraZeneca, …
Global Parp Inhibitor Market is estimated to be valued at USD 7.20 Bn in 2024 and is expected to reach USD 13.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.
Global Parp Inhibitor Market Growing Demand and Growth Opportunity 2024-2031:
The Coherent Market Insights A new report research on the Parp Inhibitor Market from 2024 to 2031 provides accurate economic, global, and country-level predictions…
Parp Inhibitor Market Overall Study Report 2024-2031 |AstraZeneca, GlaxoSmithKli …
The latest market intelligence report published by CMI with the title "Global Parp Inhibitor Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Pharmaceutical industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Parp Inhibitor Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It…
Rabies Treatment Market 2017 | Sanofi, GlaxoSmithKline, Cadila Healthcare
Global Rabies Treatment Market: Snapshot
Earlier, widespread culling of animals was embarked upon to stamp out rabies – a fatal disease caused by rabies virus transmitted from animals to humans. Domestic dogs are mainly the carriers of the virus and over 95.0% of human deaths result from dog-mediated rabies, states WHO. It also finds that Asia and Africa account for almost 95.0% of the tens of thousands of rabies deaths occurring…
Biotechnology Market – Encouraging Transformation 2025 | Genentech, GlaxoSmith …
Global Biotechnology Market: Overview
The global biotechnology market is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases. The advent of stem cell technology, nanotechnology, and cloning has also propelled this market substantially and is expected to continue aiding to this market in the years to come. However, the dearth of awareness among consumers…
Comprehensive Study On Chocolate Powder Market 2018 Global Analysis By Key Manuf …
Nestle, Mars, PepsiCo, Mondelez, GlaxoSmithKline, GlaxoSmithKline, Kanegrade are the leading companies and brands that are driving the Chocolate Powder Market. The CAGR numbers are looking quite impressive for the forecast period of 2018-2023 in the Chocolate Powder Market. The sales, import, export and revenue figures are also skyrocketing in the forecast period. The key players and brands are making their moves by product launches, their researches, their joint ventures, merges,…
